Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

TB-500 Dosing: 500mcg/Day Healing Protocol (2026)

TB-500 is a synthetic 17-amino-acid fragment of Thymosin Beta-4, containing the active actin-binding domain responsible for cell migration and tissue repair. It's a cornerstone of healing peptide protocols, especially when stacked with BPC-157. Research-contex

By Recovery & Performance Peptides Editorial Team

TB-500 is a synthetic 17-amino-acid fragment of Thymosin Beta-4, containing the active actin-binding domain responsible for cell migration and tissue repair. It's a cornerstone of healing peptide protocols, especially when stacked with BPC-157.

Research-context information only. TB-500 is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Clinical Status: No human trials exist for TB-500 specifically. All protocols are extrapolated from Thymosin Beta-4 research and animal studies. This is not medical advice.

TB-500 Dosing Table

Match your vial size below — reconstitution and dose math update automatically.

500 mcg

20 units

0.2 mL

Daily SubQStandard

750 mcg

30 units

0.3 mL

Daily SubQ

2 mg

80 units

0.8 mL

2x/week SubQLoading dose (week 1-4)

Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before injecting. Round half-units to the nearest visible mark.

10 units

0.1 mL

1 mg

40 units

0.4 mL

2x/week SubQLoading

Running TB-500? Share your protocol

Anonymous · about 20 seconds · see how yours compares

Quick Reference: Standard Protocol

Dose

500 mcg (10 units on insulin syringe)

Route

Subcutaneous injection (systemic — site doesn't matter)

Timing

AM

Frequency

Every day

Cycle

8 weeks on, 8 weeks off

Vial size

10 mg

Reconstitution

2 mL bacteriostatic water → 5,000 mcg/mL

Draw amount

10 units on insulin syringe

Storage

Refrigerate, use within 28 days

Community-reported protocol: 500 mcg daily in the morning for 8 weeks, then 8 weeks off. TB-500 works systemically, so injection site location doesn't affect efficacy. For the full TB-500 profile, vendor pricing, and stacking options, see our TB-500 peptide page.

Cycling Details

The standard cycle is 8 weeks on, 8 weeks off. Tissue remodeling and healing effects build over 4-6 weeks and continue through the full 8-week window. Community protocols describe the off period as allowing receptor sensitivity to reset, with the rationale that cycling may prevent receptor downregulation — though no direct TB-500 human trial data exists to confirm this.

Unlike some peptides, TB-500 protocols use consistent daily dosing throughout the cycle — no loading or tapering needed. The daily protocol is preferred because TB-500's half-life supports once-daily dosing, and consistent levels optimize the cellular repair processes it targets (Kim & Bhatt, 2013).

Enhanced Protocol (Community)

Note: The standard protocol above reflects the common community protocol. The enhanced protocol below is based on community experience.

2–2.5 mg twice weekly

2x per week

Weekly total

4–5 mg (vs 3.5 mg standard)

Use case

Less frequent injections, mimics TB-4 research protocols

Some users prefer twice-weekly pulsing for convenience. Weekly totals are similar, but daily dosing provides more stable tissue levels.

Routes of Administration

Subcutaneous (standard): Protocols describe injecting anywhere convenient — abdomen, thigh, upper arm. TB-500 distributes systemically regardless of site. A 29-31 gauge insulin syringe is commonly used.

Intramuscular: Occasionally used but offers no advantage over subcutaneous for a systemic peptide like TB-500.

Not recommended: Oral (peptide degradation), nasal (no data), topical (molecular weight too large).

Reconstitution Quick Reference

2 mL

5,000 mcg/mL

10 mg vial + 2 mL BAC water = 5,000 mcg/mL. A 500 mcg dose draws to 10 units on an insulin syringe under this reconstitution. One vial covers 20 days at this protocol.

Community protocols describe gentle swirling — not shaking — then refrigerating at 2-8°C and using within 28 days. For the full step-by-step walkthrough, see the TB-500 Reconstitution Guide.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Evidence-Based Dosing Protocols for Rotator Cuff Injuries

TB-500 for torn rotator cuff dosing in research contexts typically ranges from 2mg to 5mg per injection, administered subcutaneously twice weekly for 4–6 weeks. Lower doses (2–2.5mg) are sufficient for partial-thickness tears or mild strains, while full-thickness tears or post-surgical recovery often use 4–5mg. The peptide is dosed by total milligrams, not by body weight. A 150-pound individual and a 220-pound individual often use the same 2.5–5mg range. Protocol structure matters as much as dose. The loading phase runs 4–6 weeks at twice-weekly frequency, followed by a maintenance phase of 2–4mg once weekly for an additional 4 weeks if needed. Front-loading the peptide during the acute inflammatory and proliferation phases maximizes collagen deposition. Extending protocols beyond 10–12 weeks shows minimal additional benefit because the tissue has transitioned to remodeling, where mechanical loading (physical therapy, progressive resistance) drives further adaptation. Reconstitution requires bacteriostatic water at a 1:1 or 2:1 ratio depending on vial concentration. A 5mg lyophilized vial reconstituted with 2mL bacteriostatic water yields 2.5mg/mL. A 1mL insulin syringe drawn to the 1mL mark delivers the full 2.5mg dose. Store reconstituted TB-500 at 2–8°C and use within 28 days. Temperature excursions above 8°C denature the peptide structure irreversibly. The most common dosing mistake: stopping too early because subjective pain reduction occurs within 10–14 days. Pain reli…
STORAGE

Reconstitution and Storage Practices That Preserve Peptide Integrity

Lyophilized TB-500 must be reconstituted with bacteriostatic water, sterile water, or sodium chloride 0.9% immediately before use. Storing reconstituted peptide at room temperature for more than 2 hours causes measurable degradation that reduces tb-500 bioavailability by 15–20%. Once reconstituted, the peptide solution must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C accelerate hydrolysis of peptide bonds, particularly at the C-terminus where the acetyl group attached to serine-1 is susceptible to cleavage. A single overnight storage failure at room temperature doesn't render the peptide completely inactive, but it does reduce effective plasma concentrations by approximately one-third. Enough to drop below the therapeutic threshold for angiogenic signaling. The reconstitution process itself affects tb-500 bioavailability if handled improperly. Injecting bacteriostatic water forcefully into the lyophilized powder creates shear forces that denature the peptide's tertiary structure. The correct method is to inject the reconstitution fluid slowly down the side of the vial, allowing it to dissolve the powder through gentle diffusion rather than direct impact. Vigorous shaking or vortexing after reconstitution compounds the problem by introducing air bubbles that oxidize methionine residues at positions 6 and 38, which play critical roles in actin binding. We've reviewed protocols from labs that experienced unexplained drops in peptide effica…
02

Question drills

Open a question for its connected answer.

01What If Alcohol Was Consumed Within 6 Hours After TB-500 Administration?+

This is the highest-interference window. TB-500 reaches peak plasma concentration 2–4 hours post-injection, and introducing ethanol during this period directly disrupts cellular uptake and actin sequestration. Wound healing metrics in this scenario show 30–40% reduction versus TB-500 alone. The dose isn't wasted. Some benefit persists. But the protocol is significantly compromised. If this occurs in a research setting, document it as a protocol deviation and adjust statistical analysis to account for reduced treatment fidelity.

SOURCE / realpeptides.co ↗
02What If TB-500 Reconstituted Cloudy But There's No Smell or Sediment?+

Absence of odor doesn't confirm safety. Protein aggregation produces no smell but completely destroys peptide efficacy. Cloudiness without sediment typically indicates pH-induced precipitation or early-stage aggregation rather than advanced bacterial growth. The solution is still unusable for research. Test your bacteriostatic water's pH with indicator strips. If it's outside the 5.5–7.0 range, that's your culprit.

SOURCE / realpeptides.co ↗
03What If Researchers Measure Joint Mobility Outcomes Without Controlling for Inflammatory Variables?+

Control for systemic inflammation markers (C-reactive protein, erythrocyte sedimentation rate) and local cytokine profiles (synovial fluid IL-6, TNF-α) before attributing mobility changes to TB-500's direct effects. Joint range of motion can improve through multiple pathways. Reduced pain-mediated guarding, decreased synovial effusion, improved neuromuscular coordination. Many of which are downstream effects of inflammation resolution rather than tissue structural changes. A study showing 15° improvement in knee flexion with TB-500 treatment might reflect pain reduction allowing fuller voluntary movement, not necessarily enhanced cartilage integrity. Biomechanical testing, histological scoring, and imaging modalities (MRI T2 mapping for cartilage water content) provide more direct evidence of tissue-level changes.

SOURCE / realpeptides.co ↗
04What If I'm Using Pre-Filled Syringes and They Have Bubbles — Should I Discard Them?+

Do not discard pre-filled syringes solely because of visible air bubbles. Gently tap the syringe barrel with the needle pointing upward to coalesce small bubbles into one larger bubble, then slowly depress the plunger to expel the air until liquid reaches the needle hub. This recovers the peptide solution without waste. If bubbles persist after tapping and expelling, it indicates the solution was drawn too quickly or from a pressurised vial. Prevent this on future draws by using the negative pressure method described above.

SOURCE / realpeptides.co ↗
05What If My Protocol Requires 4 mL Total Volume — Can I Split It Across Routes?+

Yes. Splitting a high-volume TB-500 dose across both SubQ and IM sites is acceptable and won't compromise systemic bioavailability. Example: administer 1.5 mL SubQ in the abdomen and 2.5 mL IM in the vastus lateralis. Both depots contribute to the same plasma concentration curve within 3–4 hours. The only consideration is injection site rotation: avoid using the same SubQ or IM location more than once per week to prevent localized inflammation or lipohypertrophy.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

UK Research Cluster Hubs

TB-500 UK Research Guide BPC-157 UK Research Guide GLP-1 Peptides Complete Research Reference Retatrutide UK Research Guide Tirzepatide UK Research Guide Research-Grade Peptides Standards Guide UK Research Peptide Buying Guide Disclaimer: TB-500 is an investigational peptide not approved for human use in the UK, EU or US. All products supplied by Peptides Lab UK are for licensed in vitro and ex vivo laboratory research purposes only. Not for human consumption, veterinary use, or any therapeutic application. William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

RESEARCH

What Are the Research-Model and Delivery Considerations?

Two practical questions shape how neuroregeneration studies of Tβ4 are designed: does the peptide reach the CNS, and which models best capture human-relevant repair.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

5. Frequency — weekly vs twice-weekly

TB-500 is commonly dosed less frequently than BPC-157: Weekly — most common in tissue-repair protocols Twice-weekly — used in more acute research models or when higher sustained e…

Continue reading

Related articles

TB-500 Dosing and Reconstitution

TB-500 Dosing and Reconstitution Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption Table of Contents 1. Dosing framing for TB-500 research 2. Published…

Read article